L

ooking to end weeks of drama over an accounting scandal, Alexion Pharmaceuticals disclosed that senior management pressured employees to convince customers to order its key medicine in order to meet financial targets. The drug maker also sought to reassure Wall Street that the financial impact was limited, but some analysts called for more transparency and suggested the episode is a cautionary tale for the pharmaceutical industry.

The admission, which was contained in a regulatory filing made late Wednesday, followed an extraordinary episode that began in November, when an unnamed employee charged the drug maker engaged in fraud to hawk the Soliris rare disease treatment. The medicine generated $2.6 billion in revenue last year and currently accounts for more than 90 percent of company sales.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.